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Chondrodysplasia and Abnormal Joint Development
Associated with Mutations in IMPAD1, Encoding the
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We used whole-exome sequencing to study three individuals with a distinct condition characterized by short stature, chondrodysplasia
with brachydactyly, congenital joint dislocations, cleft palate, and facial dysmorphism. Affected individuals carried homozygous
missense mutations in IMPAD1, the gene coding for gPAPP, a Golgi-resident nucleotide phosphatase that hydrolyzes phosphoadenosine
phosphate (PAP), the byproduct of sulfotransferase reactions, to AMP. The mutations affected residues in or adjacent to the phosphatase
active site and are predicted to impair enzyme activity. A fourth unrelated patient was subsequently found to be homozygous for a prema-
ture termination codon in IMPAD1. Impad1 inactivation inmice has previously been shown to produce chondrodysplasia with abnormal
joint formation and impaired proteoglycan sulfation. The human chondrodysplasia associated with gPAPP deficiency joins a growing
number of skeletoarticular conditions associated with defective synthesis of sulfated proteoglycans, highlighting the importance of
proteoglycans in the development of skeletal elements and joints.Among the genetic disorders of the skeleton, there is
a cluster of disorderswith common features of short stature,
dysplasia of skeletal elements, and congenital joint disloca-
tions that includes Larsen syndrome,Desbuquois dysplasia,
diastrophic dysplasia, and pseudodiastrophic dysplasia
(MIM 150250, 245600, 251450, 222600, 264180, and
603799, respectively). Whereas classic (dominant) Larsen
syndrome is caused by mutations in the intracellular
filamin B,1,2 recessive Larsen syndrome and diastrophic
dysplasia are caused by defective sulfation of proteogly-
cans.3–6 The function of CANT1 (MIM 613165), the
nucleotide phosphatase homozygously mutated in some
individuals with Desbuquois syndrome, is not precisely
characterized but is likely related to the cellular handling
of sugar nucleotides and thus to proteoglycan synthesis.7,8
Here, we report on a condition consisting of congenital
joint dislocations, chondrodysplasia with short stature,
micrognathia and cleft palate, and a distinctive face
that is caused by homozygous mutations in IMPAD1
(NM_017813.3), the gene encoding Golgi-resident PAP
phosphatase (gPAPP), which is responsible for the hydro-
lysis of phosphoadenosine phosphate (PAP) to AMP.9
We first studied three patients from two unrelated
consanguineous families. All studies were conducted
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singleton case born to German parents who were first-
degree cousins. She was referred at age 23 for genetic
counseling because of unclassified skeletal dysplasia. Her
personal history included reduced length at birth with
shortening and ‘‘deformity’’ of her limbs (medical records
unavailable), micrognathia with congenital posterior cleft
of the palate (surgically repaired in infancy), and surgery
for recurrent patellar dislocation at age 16. She had been
diagnosed with hypoacusis in childhood and had worn
hearing aids since that time. Her adult height was
127 cm, and she had shortening of the limbs. Her forehead
was high, and her nasal root was broad. There was brachy-
dactyly, most marked in digits I and III bilaterally, and the
thumb had a ‘‘hitch-hiker’’ appearance similar to that seen
in diastrophic dysplasia (Figure 1D). There was limited
supination at the elbow. Both knees showed valgus defor-
mity. The feet were adducted and short, and they lacked
arching. The toes were short (Figure 1E). Her development
was not formally tested but was estimated to be in the
lower range of normal. Radiographic findings are shown
in Figure 2. No vertebral changes were observed. Note-
worthy is the brachydactyly with inhomogeneity of the
size of the metacarpal epiphyses (the epiphysis of meta-
carpal II being significantly larger), longitudinal splittinges and Institute for Genetic and Metabolic Disorders, Radboud University
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Figure 1. Clinical Features of Individuals with IMPAD1 Mutations
(A) Patient 2 at age 2 months. A high forehead with a midline hemangioma, a broad nasal bridge, a small mouth, short stature, bilateral
anterolateral dislocation of the knees, and lateral clinodactyly of the fifth toes can be seen.
(B and C) Patient 4 at age 2 days, with severe retrognathia, limited extension of the elbows, and knee dislocation.
(D and E) The median posterior palatal cleft in patients 2 and 4.
(F) The proximal position and lateral deviation of the fifth toes in patient 4 (compare with A).
(G) Patient 2 at age 9 yrs. Her height was 97 cm and thus far below the 3rd percentile for her age. The hands and feet are short, there are
multiple surgical scars, and the right leg is shorter than the left because of hip dislocation.
(H and I) Hands and feet of patient 1 at age 23 years. Note themarked brachydactyly associatedwith shortenedmetacarpals, as well as the
proximal insertion and radial deviation of digit I (so-called ‘‘hitch-hiker thumb’’). The feet are short, with forefoot adduction.of the proximal phalanx of digit I, and fusion of the capi-
tate and hamate bones (Figure 2A).
Patients 2 and 3 were two girls, both offspring of
a consanguineous couple of Turkish origin. There was
a third, unaffected sister. Patient 2 was born with short
stature, micrognathia and posterior cleft palate (the Pierre
Robin sequence), bilateral knee dislocation, and marked
lateral deviation of her fifth toes. Her forehead was high,
her eyes were prominent, her nose and mouth were small,
and her mandible was small (Figures 1A and 1C). Coronal
craniosynostosis was diagnosed at 1 year of age. Both
craniosynostosis and knee dislocations were surgically
repaired with various procedures at different ages. There
was mild hypoacusis, but speech development was
normal. Her intellectual development was moderately
delayed. Radiographic findings are shown in Figure 2.
The most significant findings were short metacarpals,
irregular size of the metacarpal epiphyses, hamate-capitate
fusion, and supernumerary carpal ossification centers
(Figure 2B); however, carpal age at birth and in the first
two years of life was not accelerated. There was dysplasia
of the hip acetabulum and the proximal femoral epiph-
yses, as well as dislocation of the knees (Figure 2E). A
moderate reduction of the intervertebral spaces was
observed, but unlike in Desbusquois dysplasia or recessive
Larsen syndrome, vertebral clefts were not observed. Her
younger sister, patient 3, was also born with short stature,
micrognathia with a median posterior palatal cleft, and
bilateral subluxation of her knees. Both of her fifth toes
were laterally deviated. Although her facial appearance
resembles that of her affected sister, with a high foreheadThe Ameand a flat face, she has no signs of craniosynostosis. At
follow-up examination at the age 2 years, her psychomotor
development was within the normal range but her stature
was markedly below the third percentile. Radiographic
findings were similar to those of her older sister, including
brachydactyly, irregular metacarpal epiphyses, and reduc-
tion of intervertebral spaces but no vertebral clefting.
Subsequently, we were consulted about a newborn for
whom a Desbuquois dysplasia was suspected; the newborn
(patient 4) had been born at 36 weeks, with a length of
42 cm and a head circumference of 33 cm, to healthy
parents from the Kerala region of India. Growth retarda-
tion had been noted in the sixth month of pregnancy via
ultrasonography. At birth, he was noted to have prominent
eyes, a flat face, severe micrognathia with posterior cleft
palate, dislocation of both knees, limited extension at
both elbows, and a peculiar abduction (lateral deviation)
of the fifth toes bilaterally (Figure 1). Radiographic exami-
nation showed short metacarpals and phalanges with an
accessory ossification center at the base of the first meta-
carpal in the left hand, whereas the right hand showed
splitting of the first metacarpal in two parts (Figure 2).
There was moderate shortening of the long bones and
subluxation of the radial heads. The vertebral contour
was irregular, but clefting was not observed. Unfortunately,
the boy succumbed to aspiration pneumonia as a complica-
tion of his palatal cleft on day 5. The similarity of this boy’s
clinical and radiographic phenotype with that of the
previous three patients prompted a direct mutation anal-
ysis of IMPAD1 (see below). The clinical features of the
four patients are summarized in Table S1 (available online).rican Journal of Human Genetics 88, 608–615, May 13, 2011 609
Figure 2. Radiographic Features of Individuals with IMPAD1 Mutations
(A) Hand X-rays of patient 4 at birth show shortening of all metacarpals, the presence of an accessory ossification center at the base of
metacarpal 1 (left hand), and splitting of the proximal phalanx of digit I into two parts.
(B and C) Findings in patient 4, recorded at birth: there is mild platyspondyly but no coronal clefting, and there is elbow joint dysplasia.
(D and E) Hand X-rays of patient 1 (D; age, 2.5 yrs) and patient 2 (E; age, 4 yrs), showing fusion between the hamate and capitate bones,
short metacarpals, irregular sizes of the distal metacarpal epiphyses (note the large size of the epiphysis of metacarpal II), and longitu-
dinal splitting of the proximal and distal phalanx of digit 1 (D). The findings are reminiscent of those in Desbuquois dysplasia.8,22,31
(F and G) Foot radiographs of patients 1 and 2, respectively (same ages as the patients in A and B). There are supernumerary tarsal bones;
all metatarsal bones are shortened, with metatarsal V being particularly short; note again the difference in size of the distal metatarsal
epiphyses in (D). Skeletal age is not accelerated. Clinodactyly of toe V in patient 2 has been corrected by casting.
(H) Pelvis and legs of patient 2 at age 3 yrs, showing proximal dislocation of the right femur and persistence of the anterior dislocation of
the right knee. Dislocation of the left knee was also present but was not appreciable on this film.Previous sequencing studies had ruled out DTDST
(SLC26A2 [MIM 606718]), CHST3 (MIM 603799), and
CANT1 mutations as the cause of the phenotype in
patients 1–3. We then decided to use a whole-exome
sequencing approach to identify the cause of this disorder
under the assumptions of an autosomal-recessive inheri-
tance and all patients having a mutation in the same
gene. We sequenced the exome (~21,000 genes) of all three
patients by using the SureSelect Human All Exon 50Mb Kit
(Agilent, Santa Clara, CA, USA) and multiplexed analysis
on a SOLiD 4 System sequencing slide (Life Technologies,
Carlsbad, CA, USA). We obtained an average of 4.3 Gb of
mappable sequence data per patient. Color space reads
were mapped to the hg19 reference genome with the
SOLiD BioScope version 1.3, which utilizes an iterative
mapping approach. On average, 82% of bases came from
the targeted genome, resulting in a mean coverage of
62-fold (Table S2). Eighty-one percent of the targeted
exons were covered more than ten times (Figure S1).
Single-nucleotide variants were subsequently called by
the Di-Bayes algorithm with high call stringency.10 Small
insertions and deletions were detected with the use of
the SOLiD Small Indel Tool. Called variants were then
combined and annotated with a custom analysis pipeline.
After initial filtering (excluding variants that had five or
fewer reads or accounted for 20% or less of all reads; see
Figure S1 and Table S2), on average, 10,693 genetic variants610 The American Journal of Human Genetics 88, 608–615, May 13,were identified, including 5185 nonsynonymous and
canonical splice-site variants (Table S2). We then applied
a prioritization scheme to identify the pathogenic muta-
tion, similar to what was done in recent studies.11–13 For
recessive diseases, it is possible that pathogenic mutations
are listed as benign polymorphisms in dbSNP or in our in-
house control data set because of unaffected individuals
carrying the variant in a heterozygous state. However,
given the rare incidence of this type of dysplasia, we
considered this unlikely. Hence, we excluded known
dbSNP132 variants as well as variants from our in-house
variant database. At the time of this study, this in-house
database contained variants from 177 in-house ‘‘exomes,’’
which contributed a total of 332,849 variants. The filtering
step that used these data further reduced the number of
candidate mutations by more than 98%, to a total of 136
variants per individual (range 100 – 160; Table S2). Next,
we prioritized these variants on the basis of the expecta-
tion of an autosomal-recessive mode of inheritance and
the assumption, based on parental consanguinity, of a
common ancestral allele. On average, 14 homozygous vari-
ants were detected per individual. Interestingly, only a
single gene, IMPAD1 (NM_017813.3), contained variants
in all three patients. For patient 1, over 95% of reads
showed a c.529G>A transition, predicting a p.Asp177Asn
substitution, whereas patients 2 and 3 showed a c.547A>C
transversion, predicting p.Thr183Pro, in over 95% of reads2011
Figure 3. Identification of Homozygous Mutations in IMPAD1 by Exome Sequencing in Patients 1, 2, and 3
(A) Schematic representation of IMPAD1 with detailed overview of exon 2, containing the identified mutations. Note that the coding
sequence of IMPAD1 is on the reverse strand of the chromosome 8 sequence, so that the chromosomal sequence corresponds to the non-
coding strand. The per-base coverage is provided with an axis to the right indicating the maximum coverage obtained per individual.
Coverage represented in gray indicates that the sequence data in the patient showed the wild-type base, whereas colored bases indicate
the detection of variants. The relative height of the color is indicative of the presence of variant in the homozygous state. Top: patient 2.
Middle: patient 3. Bottom: patient 1.
(B) Detailed zoom-in of reads showing the homozygous missense mutations. Grey arrows indicate the mapped sequence reads, with
colored bases indicating nucleotides deviating from the wild-type genomic sequence. In the nucleotides of interest, >95% of reads
show the mutated sequence.
(C) Sanger sequencing validation of the homozygous mutations in the patients 1–3. Note that the orientation is presented from the 50 to
the 30 end, representing the coding sequence.(Figure 3A). For a control cohort, we used the results from
679 control individuals from the 1000 Genomes Project,
as well as the 177 exomes present in the in-house database.
Thereby, the presence of either one of the two mutations
(as well as of the mutation subsequently identified in
patient 4; see below) was excluded in 1712 control chromo-
somes, indicating that they are not common or rare poly-
morphisms. Conventional bidirectional Sanger sequencing
confirmed homozygosity for these changes in patients 1–3,
as well as heterozygosity in the parents of the affected
siblings (Figure 3B and Figure S2). For patient 4, who was
referred later, direct sequencingof theexonsandsplice junc-The Ametions of IMPAD1 identified homozygosity for a c.559C>T
transition in exon 3, predicting a premature termination
codon (Arg187Stop) (see Table S4 and Figure S3). Parental
DNA samples of patients 1 and 4 were unavailable for
testing.
Whereas the Grantham scores for the amino acid
substitutions indicate only a small biochemical change
(p.Asp177Asn:Granthamscore23; p.Thr183Pro:Grantham
score 38), evolutionary measures at the base-pair level
suggest a strong conservation (c.529G>A: PhyloP score
4.75; c.547A>C: PhyloP score 3.91). Moreover, both
residues are located within the phosphatase domain ofrican Journal of Human Genetics 88, 608–615, May 13, 2011 611
Figure 4. Schematic Representation and Protein Modeling of IMPAD1 p.Asp177Asn and p.Thr183Pro Mutations
(A) Schematic representation of the predicted effect at the protein level. Domains and functions are provided in different colors, with the
binding domain harboring the mutations indicated by an underlined protein sequence in a green shaded box.
(B) Evolutionary conservation of the protein sequence throughout evolution. Mutated amino acids are indicated by yellow boxes.
(C) Overview of the protein in ribbon presentation. Middle: the protein is colored gray, and the side chains of the mutated residue are
colored magenta and shown as small balls. Left and right: Close-up of the p.Thr183Pro and p.Asp177Asnmutations. Side chains of both
the wild-type and the mutant residue are shown and are colored green and red, respectively.IMPAD1 and are completely conserved throughout evolu-
tion (Figures 4A and 4B). In the UniProt database, IMPAD1
is still listed as a probable myoinositol monophosphatase
on the basis of the original description,14 and IMPAD1 resi-
dues 176–179 are predicted to be substrate binding on the
basis of similarity with other phosphatases.
Because the three-dimensional structure of gPAPP
(Uniprot entry Q9NX62) is unknown, protein modeling
was performed for the mutations p.Asp177Asn and
p.Thr183Pro via two approaches. The HOPE program15
was able to build a model by using PDB file 2WEF, which
shares a 26% sequence identity with IMPAD1. In parallel,
three-dimensional models for the wild-type IMPAD1, as
well as those for polypeptides containing either one of
the two mutations, were obtained from the ESyPred3D
site,16 also with 2WEF used as a template, and analyzed
with the use of the SPDBV software version 4.0.1. Molec-
ular modeling via both programs shows that Asp177 and
Thr183 are located in, and close to, the substrate binding
pocket (see Figure S4). For p.Asp177Asn, the loss of the
negatively charged amino acid is expected to affect the
binding of an essential magnesium ion, thereby most612 The American Journal of Human Genetics 88, 608–615, May 13,likely directly disturbing the phosphatase activity (Fig-
ure 4C, Figure S4). Thr183 is located at the C terminus of
an alpha helix that contains important substrate binding
site residues at its N-terminal side, including residue
Asp177. Replacing Thr183 by proline will disturb this helix
because proline has no free hydrogen in its backbone (Fig-
ure 4C, Figure S4). The helix-breaker effect of proline re-
sulting from its rigidity is well known.17 The p.Arg187Stop
mutation identified in patient 4 predicts the truncation
of the protein with the loss of 173 amino acid residues
(out of a total of 359) at the carboxy-terminal end; if the
corresponding mRNA escapes nonsense-mediated decay,
the truncation is likely to have a major effect on the
folding of the protein.
Impad1 inactivation has been associated with skeletal
dysplasia and abnormal joint formation in mice by three
independent groups. Mitchell et al. generatedmice bearing
gene-trap alleles and observed a short limb and trunk
phenotype produced by the trapping of the gene for
a membrane protein with similarity to inositol monophos-
phatases.14 Sohaskey et al. studied this mouse strain
in more depth and observed a severe chondrodysplasia2011
Figure 5. Schematic Representation of
Sulfate Activation and Sulfation Pathways
Extracellular sulfate is taken up from the
extracellular space through a sulfate-chlo-
ride exchanger (SLC26A2, DTDST) and
subsequently activated to its high-energy
form, phosophoadenosine phosphosul-
phate (PAPS). A PAPS translocase that
shuttles PAPS from the cytoplasm to the
endoplasmic reticulum has been identi-
fied in zebrafish. PAPS is the sulfate donor
for most sulfotransferase reactions both in
the cytoplasm and in the endoplasmic
reticulum and Golgi complex, such as
those required for sulphation of nascent
proteoglycans. Inhibition of sulfotransfer-
ase reactions by PAP (dashed line) has
been demonstrated in vitro. Efflux of
AMP from the endoplasmic reticulum
through a transporter or exchanger
(dotted line) has been postulated but not
demonstrated. Known genetic defects
leading to human osteoarticular pheno-
types are marked by circled numbers: 1,
SLC26A2/DTDST (sulfate transporter); 2,
PAPSS (PAPS synthase); 3, CHST3 (chon-
droitin 6-sulfotransferase); 4, CHST14
(dermatan 4-sulfotransferase); 5, IMPAD1
(Golgi-resident phosphoadenosine phos-
phate phosphatase, gPAPP).including ectopic interphalangeal joints, leading to the
denomination of the phenotype as ‘‘JAWS’’ for ‘‘joints
abnormal with splitting.’’18 They observed delayed and
disorganized maturation of growth-plate chondrocytes,
impaired sulfation of chondroitin, and abnormal metabo-
lism of the chondroitin sulfate proteoglycan aggrecan, but
a functional characterization of the specific enzymatic
function of Impad1 was not performed.18 Frederick et al.
explored the enzymatic properties of Impad1 in vitro and
showed that when targeted to the Golgi, Impad1 had
a strong phosphoadenosine phosphate 3-nucleotidase (or
PAP phosphatase, PAPP) activity.9 Subsequently, they
made use of a different Impad1 gene-trap cell line to
generate transgenic mice and noted that the chondrodys-
plasia phenotype was associated with markedly reduced
sulfation of chondroitin and heparan proteoglycans.9 To
explain the sulfation defect associated with gPAPP inacti-
vation, they suggested that the physiologic role of gPAPP
might be to remove the PAP that remains after the transferThe American Journal of Humanof the high-energy sulfate group from
PAPS to the sulfation substrate (such
as the nascent chondroitin chains)
in the Golgi (Figure 5).9 Hydrolysis
of PAP to AMP and phosphate
would prevent product inhibition
on the sulfotransferase reactions and
possibly allow for reverse transport
of AMP from the Golgi to the cyto-
plasm (Figure 5).9 Both groups of
researchers placed their findings inthe context of skeletal dysplasias related to proteoglycan
undersulfation and suggested that the Impad1-inactivated
mouse was a possible model for a human disorder yet to
be identified.9,18
We now report on the human phenotype associated
with IMPAD1 mutations and confirm the predictions
made on the basis of the mouse knockouts and the
biochemical studies. Although the phenotype in our
patients is distinct, the differential diagnosis has included
disorders associated with disturbed proteoglycan synthesis
and sulfation such as diastrophic dysplasia, recessive
Larsen syndrome, and Desbuquois dysplasia. Longitudinal
splitting of phalanges, as seen in the JAWS mouse
model and in our patient 1, can be seen in severe DTDST
disorders, as well as in disorders of chondroitin sulfate
synthesis (CHSY1 [MIM 608183]),19,20 whereas the pres-
ence of additional phalangeal ossification centers is
the hallmark of CANT1-related Desbuquois dysplasia.21
The a priori differential diagnostic considerations in ourGenetics 88, 608–615, May 13, 2011 613
patients; the findings of different, highly disruptive substi-
tutions in IMPAD1 in three unrelated families; and
the similarity between the clinical and radiographic find-
ings in our patients and the findings in the existing
mouse models leave no doubt as to the causative role of
the IMPAD1 mutations and allow us to delineate a
nosologic entity that we suggest be designated as ‘‘chon-
drodysplasia with joint dislocations, gPAPP type’’ (in style
with the most recent nosology)22 or, more simply, gPAPP
deficiency.
IMPAD1 analysis should be included along with CHST3
and CANT1 in the diagnostic algorithm for infants pre-
senting with congenital dislocations, chondrodysplasia,
and short stature. It seems that the differential diagnosis
of this entity must be made in consideration with
diastrophic dysplasia, Desbuquois dysplasia, and recessive
Larsen syndrome. The absence of significant vertebral
anomalies may help in distinguishing gPAPP deficiency
from Desbuquois syndrome and from CHST3 deficiency,
and the presence of knee dislocations and a facial
phenotype may distinguish it from diastrophic dysplasia.
However, the identification of additional individuals
with gPAPP deficiency, particularly by screening of those
who have tested negative for CHST3 and CANT1 muta-
tions, may further delineate the phenotypic spectrum
resulting from IMPAD1 mutations.
Desbuquois dysplasia has been considered to be hetero-
geneous with respect to the presence or absence of
‘‘typical’’ hand abnormalities.21,23 However, CANT1muta-
tions are found in both the group with and the group
without typical hand abnormalities,7,8 and some individ-
uals in both phenotypic groups are negative for CANT1
mutations. Although the precise role of CANT1 in the
pathogenesis of Desbuquois dysplasia remains to be eluci-
dated, the notion that both CANT1 and IMPAD1 are nucle-
otide phosphatases further supports a role of CANT1 in
proteoglycan synthesis.
IMPAD1 deficiency can be added to the growing list of
defects of proteoglycan synthesis associated with a skeletal
and articular phenotype, a list that includesB4GALT7 (MIM
604327),24,25 EXT1 (MIM 608177), EXT2 (MIM 608210),26
andCHSY1,19,20 and those affectingproteoglycan sulfation,
such as DTDST,3,4 PAPSS (MIM 603005),27 CHST3,5,6,28
and CHST14 (MIM 608429).29,30 The large number of
enzymes involved in proteoglycan synthesis and sulfation
suggests that more such genetic disorders may exist. More
broadly, this study provides additional proof that exome
sequencing can be instrumental in finding the remaining
genes associated with clinical and molecularly heteroge-
neous disorders, especially when combined with careful
phenotypic characterization and homogeneous patient
selection.Supplemental Data
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